Gilead Sciences Inc (NASDAQ:GILD)
| 75.57 Delayed Data As of 4:00pm ET |  +0.04 / +0.05%Today’s Change | 61.45 Today|||52-Week Range 89.74 | -11.97% Year-to-Date |
Five Year Financial Summary
| All Currency in US Dollars | 4 Year Trend | |||||
|---|---|---|---|---|---|---|
2015 | 2016 | 2017 | 2018 | |||
| Operating Activities | Net Income / Starting Line | 18.1B | 13.5B | 4.6B | 5.5B | |
| Depreciation | 1.1B | 1.2B | 1.3B | 1.4B | ||
| Total Other Cash Flow | 355.0M | 780.0M | 942.0M | 2.2B | ||
| Funds From Operations | 19.2B | 15.3B | 6.8B | 9.3B | ||
| Funds From/For Other Operating Expenses | -1.2B | -1.4B | -5.1B | 939.0M | ||
| Net Cash Flow - Operating Activities | 20.3B | 16.7B | 11.9B | 8.4B | ||
| Investing | Increase In Investments | -17.2B | -26.0B | -23.3B | -10.6B | |
| Decrease In Investments | 5.5B | 14.7B | 18.3B | 25.9B | ||
| Capital Expenditures | -747.0M | -748.0M | -590.0M | -924.0M | ||
| Net Assets From Acquisitions | 0.00 | 0.00 | -10.4B | 0.00 | ||
| Net Cash Flow Investing | -12.5B | -12.0B | -16.1B | 14.4B | ||
| Financing | Short Term Borrowings | 0.00 | 0.00 | 0.00 | 0.00 | -- |
| Long Term Borrowings | 10.7B | 6.2B | 9.0B | 0.00 | ||
| Long Term Debt Reduction | -997.0M | -2.0B | -1.8B | -6.3B | ||
| Net Proceeds Stock Sale | 319.0M | 208.0M | 234.0M | 289.0M | ||
| Common Preferred Redeemed | -10.0B | -11.0B | -954.0M | -2.9B | ||
| Common Dividends | -1.9B | -2.5B | -2.7B | -3.0B | ||
| Cash Dividends Paid - Total | -1.9B | -2.5B | -2.7B | -3.0B | ||
| Other Sources - Financing | 773.0M | 194.0M | 0.00 | 0.00 | ||
| Other Uses - Financing | 3.9B | 561.0M | 330.0M | 486.0M | ||
| Net Cash Flow - Financing | -5.0B | -9.3B | 3.4B | -12.3B | ||
| Exchange Rate | Effect of Exchange Rate on Cash | -67.0M | 41.0M | 137.0M | -85.0M | |
| Net Change In Cash | 2.9B | -4.7B | -778.0M | 10.4B | ||
